Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Tolerability of Single and Multiple Doses of LB-102 in Healthy Adults

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04187560
Recruitment Status : Completed
First Posted : December 5, 2019
Last Update Posted : December 10, 2020
Sponsor:
Information provided by (Responsible Party):
LB Pharmaceuticals Inc.

Brief Summary:
A Single Ascending Dose (SAD; Part A) and Multiple Ascending Dose (MAD; Part B) Phase 1 Study of LB-102 N-Methyl amisulpride) in healthy volunteers. The primary objective is to evaluate the safety and the tolerability of a single oral dose (SAD) and multiple oral doses (MAD) of LB-102 as compared to placebo. The secondary objectives are to evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) of LB-102.

Condition or disease Intervention/treatment Phase
Schizophrenia Drug: LB-102 Phase 1

Detailed Description:

This is a Phase 1, randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerability, and pharmacokinetics of LB-102 in healthy subjects. The study will consist of two parts: Part A - Single Ascending Dose and Part B - Multiple Ascending Doses. There will be 5 cohorts in Part A and 3 Cohorts in Part B of this study. Each cohort consists of 8 subjects, with 6 subjects assigned to LB-102 and 2 subjects assigned to placebo.

In Parts A and B, eligible subjects will be randomized on Day 1 (pre-dose) to placebo (n=2) or LB-102 (n=6). Eligible subjects will receive 1 dose on Day 1 (Part A) or 13 doses on Days 1-7 (Part B) of placebo or LB-102.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 64 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Double (Participant, Care Provider)
Primary Purpose: Treatment
Official Title: A Randomized, Double-blinded, Placebo-controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LB-102 Administered Orally to Healthy Subjects
Actual Study Start Date : January 22, 2020
Actual Primary Completion Date : July 1, 2020
Actual Study Completion Date : November 9, 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: Part A Cohort 1
LB-102 50 mg (n=6) or Matching Placebo (n=2) x 1 day
Drug: LB-102
(N-Methyl amisulpride)
Other Name: Active Drug

Active Comparator: Part A Cohort 2
LB-102 15 mg (n=6) or Matching Placebo (n=2) x 1 day
Drug: LB-102
(N-Methyl amisulpride)
Other Name: Active Drug

Active Comparator: Part A Cohort 3
LB-102 100 mg (n=6) or Matching Placebo (n=2) x 1 day
Drug: LB-102
(N-Methyl amisulpride)
Other Name: Active Drug

Active Comparator: Part A Cohort 4
LB-102 200 mg (n=6) or Matching Placebo (n=2) x 1 day
Drug: LB-102
(N-Methyl amisulpride)
Other Name: Active Drug

Active Comparator: Part A Cohort 5
LB-102 150 mg (n=6) or Matching Placebo (n-2) x 1 day
Drug: LB-102
(N-Methyl amisulpride)
Other Name: Active Drug

Active Comparator: Part B Cohort 6
LB-102 50 mg (n=6) or Matching Placebo (n=2) BID x 7 days (QD on Day 7)
Drug: LB-102
(N-Methyl amisulpride)
Other Name: Active Drug

Active Comparator: Part B Cohort 7
LB-102 100 mg (n=6) or Matching Placebo (n=2) BID x 7 days (QD on Day 7)
Drug: LB-102
(N-Methyl amisulpride)
Other Name: Active Drug

Active Comparator: Part B Cohort 8
LB-102 75 mg (n=6) or Matching Placebo (n=2) BID x 7 days (QD on Day 7)
Drug: LB-102
(N-Methyl amisulpride)
Other Name: Active Drug




Primary Outcome Measures :
  1. Percentage of participants who experience at least one treatment-emergent adverse event (TEAE) [ Time Frame: Day 8 (Part A) or Day 15 (Part B) ]
    A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug. A TEAE may also be a pre-treatment adverse event or a concurrent medical condition diagnosed prior to the date of first dose of study drug, which increases in intensity after the start of dosing.


Secondary Outcome Measures :
  1. Tmax: Time to Reach the Maximum Plasma Concentration [ Time Frame: Days 1, 2 and 3 (Part A) Days 1 through 9 (Part B) ]
    Time to reach the maximum observed plasma concentration for LB-102 and LB-102 metabolite amisulpride after a single dose (Day 1) and multiple dosing (Day 7).

  2. Cmax: Maximum Observed Plasma Concentration [ Time Frame: Days 1, 2 and 3 (Part A) Days 1 through 9 (Part B) ]
    Maximum observed plasma concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve. Cmax will be measured for LB-102 and LB-102 metabolite amisulpride after a single dose (Day 1) and multiple dosing (Day 7).

  3. AUC(0-tlqc): Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration [ Time Frame: Days 1, 2 and 3 (Part A) Days 1 through 9 (Part B) ]
    AUC(0-tlqc) is a measure of total plasma exposure to a drug from time 0 to time of the Last Quantifiable Concentration and will be measured for LB-102 and LB-102 metabolite amisulpride after a single dose (Day 1) and multiple dosing (Day 7)

  4. AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours Postdose [ Time Frame: Days 1, 2 and 3 (Part A) Days 1 through 9 (Part B) ]
    AUC(0-24) is a measure of total plasma exposure to the drug from Time 0 to 24 hours post-dose for LB-102 and LB-102 metabolite amisulpride after a single dose (Day 1) and multiple dosing (Day 14).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

Subjects may be included in the study only if they meet all of the following criteria:

  1. Competent to provide informed consent.
  2. Voluntarily provide informed consent.
  3. Healthy adult male and female subjects between 18 to 55 years of age inclusive at the screening visit.
  4. Body Mass Index (BMI) ≥ 18 and ≤ 30 kg/m2 at screening visit.
  5. Subjects must be in good general health as determined by medical history and physical examination with no clinically significant medical findings and no history of significant medical disease (e.g. cardiovascular, pulmonary, renal, etc.) or acute condition with the past 30 days.
  6. Have normal clinical laboratory test results and ECG, which are not considered to be clinically significant by the investigator.
  7. Female subjects of child-bearing potential must agree to use two methods of an acceptable method of birth control (e.g., condom and spermicide, intrauterine device (IUD), oral contraception which has been stable for 30 days) and at least 90 days after stopping the investigational product. Female subjects using oral contraception whose partner consistently uses condoms or who is vasectomized is also acceptable.
  8. Male subjects must be surgically sterile or practicing at least one method of contraception, from initial study drug administration through 90 days after administration of the last dose of study drug:
  9. Male subjects must agree to abstain from sperm donation through 90 days after administration of the last dose of investigational drug.

Exclusion Criteria:

Subjects will be excluded from the study for any of the following reasons:

  1. Are pregnant or lactating.
  2. Have a history or presence of significant cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, or neurological disorders which, in the opinion of the investigator, increases the risk of the study drug or may confound the interpretation of study measures.
  3. Clinically significant abnormal findings on physical examination, vital signs, or ECG.
  4. History or presence of psychiatric or neurological disease or condition.
  5. History of seizures.
  6. Subject with any history or current evidence of suicidal behavior.
  7. Unwilling to complete any planned study assessments, including the Columbia-Suicide Severity Rating Scale (CSSRS).
  8. Recent history of alcohol or drug abuse (within the last two years).
  9. Any use of tobacco or tobacco-containing products (cigarettes, pipes, etc.) within one month prior to screening.
  10. Have a history of blood donation in excess of 500 mL of blood within 30 days prior to Screening.
  11. Have received treatment with an investigational drug or device within 30 days prior to Screening.
  12. Use of any prescription or over the counter medication, herbal medications, vitamins, or supplements within 14 days prior to study drug administration.
  13. Have a positive test for human immunodeficiency virus (HIV) antibodies 1 and 2, Hepatitis B surface antigen or Hepatitis C antibody.
  14. Any subject who is known to be allergic to the study drug or any components of the study drug.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04187560


Locations
Layout table for location information
United States, Ohio
Medpace Clinical Pharmacology LLC
Cincinnati, Ohio, United States, 45227
Sponsors and Collaborators
LB Pharmaceuticals Inc.
Investigators
Layout table for investigator information
Principal Investigator: Lukasz Biernat, MD Medpace, Inc.
Additional Information:
Study Data/Documents: Clinical Study Report  This link exits the ClinicalTrials.gov site

Layout table for additonal information
Responsible Party: LB Pharmaceuticals Inc.
ClinicalTrials.gov Identifier: NCT04187560    
Other Study ID Numbers: LB-102-001
First Posted: December 5, 2019    Key Record Dates
Last Update Posted: December 10, 2020
Last Verified: December 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Schizophrenia
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders